ReNeuron Group plc (LON:RENE – Get Free Report)’s share price crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of GBX 3.38 ($0.04) and traded as high as GBX 3.50 ($0.05). ReNeuron Group shares last traded at GBX 3.38 ($0.04), with a volume of 177,373 shares changing hands.
ReNeuron Group Stock Performance
The firm has a market capitalization of £1.93 million, a PE ratio of -37.50 and a beta of 0.83. The company has a current ratio of 1.51, a quick ratio of 2.02 and a debt-to-equity ratio of 14.25. The business’s 50 day simple moving average is GBX 3.38 and its two-hundred day simple moving average is GBX 3.40.
ReNeuron Group Company Profile
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease.
Read More
- Five stocks we like better than ReNeuron Group
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- Roth IRA Calculator: Calculate Your Potential Returns
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.
